Actively Recruiting

Phase Not Applicable
Age: 30Years - 65Years
All Genders
NCT07504029

Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides

Led by Chung Shan Medical University · Updated on 2026-03-31

12

Participants Needed

1

Research Sites

20 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prediabetes is a metabolic condition characterized by elevated blood glucose levels that are higher than normal but below the diagnostic threshold for diabetes. Early intervention to improve glycemic control may help delay the progression to type 2 diabetes. Momordica charantia (bitter melon) peptides have been reported to possess potential glucose-regulating effects. This study aims to evaluate the effects of BmpP® bitter melon peptide supplementation on glycemic control in adults with prediabetes. This study is designed as a 12-week single-arm, open-label clinical trial. Approximately 12 adults aged 30-65 years with prediabetes will be recruited. Participants will consume bitter melon peptide capsules three times daily before meals for 12 weeks. Primary outcomes include fasting blood glucose, postprandial glucose response, and HbA1c levels. The findings of this study may provide preliminary evidence regarding the potential role of bitter melon peptides in blood glucose regulation.

CONDITIONS

Official Title

Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides

Who Can Participate

Age: 30Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 30 to 65 years, male or female
  • Prediabetes defined by any of the following: fasting blood glucose 100-125 mg/dL, HbA1c 5.7-6.4%, or 2-hour OGTT glucose 140-199 mg/dL
  • Body mass index between 24 and 35 kg/m² with waist circumference recorded (men 60 cm; women 60 cm)
  • Stable lifestyle including diet, physical activity, and sleep habits for the past three months
  • No use of blood glucose-regulating supplements before or during the study
  • Willing to comply with study procedures and complete assessments
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Diagnosis of type 2 diabetes mellitus (HbA1c 6.5% or physician diagnosis)
  • Current use of antidiabetic medications like metformin or insulin
  • Use of medications affecting blood glucose such as corticosteroids or antipsychotics
  • Severe liver, kidney, heart disease, active cancer, or gastrointestinal malabsorption
  • Pregnant, breastfeeding, or planning pregnancy
  • Body weight change over 7% in past three months or on weight-loss diet
  • History of alcohol abuse or substance misuse
  • Working night or rotating shifts
  • Allergy to any study product component
  • Participation in another clinical trial within past month or antibiotic use within 8 weeks
  • Being a student, staff, or employee related to the investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chung Shan Medical University

Taichung, Taiwan

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here